SINGAPORE, Oct. 23, 2023 /PRNewswire/ — The Alliance For Good, in partnership with Nanyang Technological University (NTU) and the Asia Family Office Association, announces the Business and Philanthropy Forum 2023 on November 9 and 10 in Singapore.

Themed "Asia Vision: Wealth and Purpose," the Forum convenes global leaders, family offices, philanthropists, investors, academics, policymakers, and nonprofits to discuss aligning wealth with purpose.

Asia is witnessing a surge in single-family offices, with 59% choosing Singapore as their preferred destination. In 2022, Singapore had 1,100 family offices[1], a sevenfold increase since 2017. The Forum aims to equip next-generation family businesses and family office leaders with insights to navigate today’s landscape and harness resources for impact by facilitating peer-to-peer learning, open dialogue, and collaboration.

With a Pan-Asian focus, the Forum underscores regional cooperation in addressing global challenges. As a pioneering event since 2016, it advocates value-based investment and cross-sector innovation at the intersection of geopolitics and technology.

The programme features over 15 keynote speeches and 25 breakout sessions on strategic philanthropy, family business as a force for good, sustainable investment, the future of finance, and more.

Distinguished speakers include Benjamin Fok Chun-yue (Fok Ying Tung Foundation), Berry Liberman (Small Giants), Stefan Messer (Messer Group), Drayton McLane Jr. (McLane Group), Abdulla Al Gurg (Abdulla Al Gurg Global Investments), Basma Al Zamil (Al Zamil family), Laurence Lien (Asia Philanthropy Circle), Zhu Zining (Hopson Development), Hou Yameng (Proya Cosmetics), Tan Eng Chye (National University of Singapore), and Tan Tai Yong (Singapore University of Social Sciences).

Previous editions of the Forum featured esteemed speakers such as Howard Warren Buffett, Camilla Rockefeller (David Rockefeller Fund), Maya Soetoro-Ng (sister of Barack Obama), Victor Koo (Founder of Youku), Kyungsun Chung (Hyundai family member), Masagos Zulkifli, Minister for Social and Family Development, Singapore, and Desmond Tan, Minister of State, Prime Minister’s Office, Singapore, who have all contributed to its legacy.

Join us at this premier platform to empower the next generation, foster idea exchange, and drive global impact.

For details and tickets, visit https://bpforum.org and https://lu.ma/nuxrrrf7.

[1] https://www.edb.gov.sg/en/our-industries/family-office.html

About Alliance For Good

Alliance For Good (AFG) is a distinguished philanthropy network founded in Singapore with a strong presence in Asia. Our core mission is to facilitate impactful change by servicing the region’s families, family offices, foundations, firms, and financial institutions. AFG has established itself as a leader in the field, specialising in organising large-scale events in both Singapore and Mainland China. Our most prominent endeavour, the Business and Philanthropy Forum, has been a resounding success over the past six years. This flagship event attracts a diverse audience of global philanthropists, Ultra-High-Net-Worth Individuals (UHNWI), Family Offices, Venture Capitalists, Tech Founders and C-suite executives from across Asia and worldwide.

Source : 2023 Business and Philanthropy Forum by Alliance For Good: Catalysing Next-Gen Leaders to Drive Change

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ — Sendbird announces the integration of Meta’s open-source Large Language Model (LLM), Llama2, into its AI-based communication platform. This strategic move solidifies Sendbird’s position at the forefront of the industry, granting enterprise customers unparalleled flexibility in utilizing generative AI chatbot while adhering to their specific operational strategies and security preferences.

Sendbird now offers its customers the option to utilize Meta’s Llama2.

Meta’s Llama2 is an open-source LLM trained on a vast dataset of billions of words, freely available for anyone to use according to their specific needs. The advantage of Llama2 is its open-source nature, allowing users to tailor its utilization according to their precise requirements, system configurations, training methods, and use cases. This adaptability significantly reduces the risk associated with exposing or exploiting sensitive corporate information during the LLM training process. Not only does it instill greater trust in the system, but it also ensures compliance with ethical data usage standards and legal regulations.

Recognizing the importance of data security, Sendbird now offers enterprise customers the option to leverage the open-source LLM, Llam2. This move enhances the protection of corporate data residing on Sendbird’s servers, mitigating potential threats of data leaks and unauthorized access. Sendbird is dedicated to further developing technologies that fine-tune Llama2 for enterprise clients, striking a harmonious balance between data security and optimized LLM performance.

Mr. Kim Dongshin, CEO of Sendbird, expresses his enthusiasm for this innovative integration. He emphasized how the incorporation of Llma2 caters to Sendbird’s diverse clientele, encompassing businesses, financial institutions, and small enterprises. It offers them a spectrum of choices and the flexibility required to harness the potential of generative AI, ensuring that Sendbird’s customers consistently have access to cutting-edge communication tools for seamless client interactions.  

Sendbird’s latest offering, an AI chatbot featuring Llama2, is now available for deployment. From October 20, businesses can embrace this innovative technology via web and mobile apps, making a significant advancement in the domain of AI-driven communication.

For further information and firsthand experience, please visit the following link: https://Sendbird.com/products/open-source-llama2-integration/

About Sendbird:

As a member of the Global Digital Innovation Network (formerly known as Born2Global Centre), Sendbird is a technology company that provides leading enterprise chat solutions. Their comprehensive communication platform includes chat, voice, video, and management desk services. Sendbird enables  swift integration of these features into various applications and websites, supporting over seven billion messages monthly. Prominent international clients, including Rakuten, PayPay, AirAsia, Reddit, Hinge, Paytm, as well as leading South Korean companies like SSG.com, KB Kookmin Bank, and Baedal Minjok, have successfully leveraged Sendbird’s technology. Having secured over $200 million in investments from top Silicon Valley VCs, Sendbird is headquartered in Silicon Valley, USA.

Source : Sendbird Expands Customer Choices through Integration of Meta's Llama2

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Oct. 23, 2023 /PRNewswire/ — CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces today that it has discovered the Shenfu deep coalbed methane (CBM) field in China, adding proved gas in-place of over 100 billion cubic meters.

The Shenfu deep CBM field is located in Yulin, Shaanxi Province at the eastern edge of Ordos Basin. With continued research and exploration, the Company has advanced its understanding of deep coalbed methane formation mechanism, reservoir transformation and differentiated drainage technology, which have led to the successful discovery of the Shenfu deep CBM field. The discovery well SM2-33-CH1 encounters 16.5 meters of coal seam at a burial depth of approximately 2,011 meters, which is tested to produce approximately 19,000 cubic meters per day after fracturing operations. The Chinese governmental authorities have evaluated and approved the proved gas in-place of over 110 billion cubic meters, making it China’s first large deep CBM field of the scale. It is another major onshore discovery by CNOOC Limited after the discovery made in Linxing, Shanxi Province, with similar proved gas in-place volumes.

Mr. Xu Changgui, Deputy Chief Exploration Engineer of the Company, said, "The discovery of the Shenfu deep CBM field demonstrates the broad prospect of exploration and development in the eastern edge of the Ordos Basin. It will provide important guidance for our exploration in similar basins and facilitate the growth of our reserves and production of unconventional oil and gas."

Mr. Zhou Xinhuai, CEO and the President of the Company, said, "The discovery lays a solid foundation for the Company to build a large onshore gas production base, which will tap up to one trillion cubic meters of proved gas in-place. To that end, we will continue to step up our efforts in the exploration and development of onshore unconventional gas, to increase our reserves and production, and to contribute to the high-quality development of the Company."

— End —

Notes to Editors:

More information about the Company is available at http://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations, including but not limited to those associated with fluctuations in crude oil and natural gas prices, macro-political and economic factors, changes in the tax and fiscal regimes of the host countries in which we operate, the highly competitive nature of the oil and natural gas industry, environmental responsibility and compliance requirements, the Company’s price forecast, the exploration and development activities, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: [email protected]

Mr. Bunny Lee
Porda Havas International Finance Communications Group
Tel: +852 3150 6707
Fax: +852 3150 6728
E-mail: [email protected]

Source : CNOOC Limited Discovers Deep Coalbed Methane Field with Proved Gas In-place of over 100 Billion Cubic Meters

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Strategic equity investment follows joint development agreement between the two companies

TORONTO, Oct. 23, 2023 /PRNewswire/ — Inmotive announced today that Suzuki is investing in its company, further supporting its Ingear™ 2-speed EV transmission development. The investment is via the Suzuki Global Ventures (SGV) fund, which was established in October 2022 and aims to accelerate the co-creation of activities between start-ups and Suzuki in addition to creating new businesses and business models.

This investment follows the signing of a joint development agreement (JDA) between the two companies in January 2023. The JDA specifies how Inmotive’s Ingear 2-speed EV transmission is developed to extend range and reduce cost for future Suzuki electric vehicles. To date, the JDA with Suzuki is progressing according to plan and all deliverables have been met.

"Having Suzuki as a partner has been a tremendous opportunity for the commercialization of the Ingear and we are excited to have the company extend its support of our eco-friendly technology with their recent investment," said Paul Bottero, CEO, Inmotive. "It is through collaborations and investments like this that we will be able to bring our vision of accelerating the global evolution to affordable zero-emission mobility to life."

"This strategic investment further enhances our close working relationship with Inmotive and underscores our commitment to making investments that address key issues globally as well as our dedication to the Ingear technology," said Toshihiro Suzuki, President, Suzuki Motor Corporation. "We are taking great strides toward a successful deployment of the Ingear on Suzuki vehicles and look forward to continuing down that path." 

About Inmotive Inc. 

Inmotive is the Canadian based inventor of the Ingear, an ultra-efficient multi-speed powertrain technology for a wide range of applications. The Ingear reduces EV cost and weight, while extending range and increasing torque, acceleration, gradeability and top speed. It is protected with 23 patents issued and 46 patents pending. Inmotive is headquartered in Toronto, Canada, with offices in Europe and China. More information is available at www.inmotive.com.  

About Suzuki Motor Corporation

Suzuki, which has the company motto "Develop products of superior value by focusing on the customer," currently offers products in three mobility categories — automobiles, motorcycles, and outboard motors. The company aims to remain indispensable to people by staying closely attuned to lives and providing mobility.

Media Contact
Brittney Popa
MBE Group (Inmotive)
(231) 675-1692
[email protected]

Source : Inmotive Receives Strategic Investment from Suzuki

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ — iCOOP KOREA held the <iN Natural Dream 2023 International Symposium> ‘New challenges for the healing of humanity and the earth in the era of polycrisis’ at the Lifecare Hall of Goesan Natural Dream Park for two days from October 18th to 19th.

Cancer Prevention Scholars and Climate Crisis Experts from Korea, US and Japan Come Together iCOOP KOREA Holds the ‘2023 International Symposium’

This symposium was designed as an opportunity for scholars and experts from Korea, the United States, and Japan to gather and share new challenges and discuss open cooperation in depth to respond to the rapidly increasing cancer and climate crisis worldwide. The first day’s discussion was on ‘cancer’, a grave concern today. The second day was about measures to respond to the climate crisis.

Professor Thomas Seyfried of Boston College, USA, who gave the keynote speech, emphasized that "cancer is a metabolic disease, not a disease caused by genetic mutation" and proposed a new approach to treating cancer and preventing recurrence. Next, at the book concert, Director Takashi Funato, author of the book ‘Lifestyle Habits to Cure Cancer’, director of Reborn Horado, Japan, spoke. As a former surgeon, he shared his experiences of witnessing patients recovering from a cancer diagnosis and introduced five lifestyle habits that help cancer treatment. Chitose Arai, vice president of the Japan Consumer Cooperatives Union (JCCU), presented various practices of Japanese cooperatives that have been creating healthy lives for their members beyond simple consumption in a session titled ‘Innovation in cooperatives that create healthy lives together.’

Kim Jeong-hee, president of iCOOP and one of the organizers of this symposium, said, "We prepared this international symposium in light of the need for humankind to have common awareness and response regarding our health and the global environment in which we live. Goesan Natural Dream Park, where this event is taking place, is a space containing the wishes and actions of iCOOP members to prevent disease and respond to the climate crisis."

About 300 people attended, including experts in Korea, the United States, and Japan, ICA-AP(International Cooperative Alliance Asia pacific region) members, iCOOP members, medical officials, and civic groups.

Meanwhile, ‘iN Natural Dream’ has developed foods with high anti-cancer properties and published research papers in an international academic journal, proving their anti-cancer effects. Under the slogan," The Best Foods Prevent Cancer" the company carries out cancer prevention and recurrence prevention activities, developing a sincere Lifecare movement.

Source : Cancer Prevention Scholars and Climate Crisis Experts from Korea, US and Japan Come Together, iCOOP KOREA Holds the '2023 International Symposium'

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

The ORR (objective response rate) and the DCR (disease control rate) in the frontline setting of glecirasib (KRAS G12C Inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100% respectively in all dose groups of advanced non-small cell lung cancer (NSCLC), among which, in the dose group of 800 mg glecirasib (once daily) in combination with 2 mg JAB-3312 (once daily for 1 week on, then 1 week off), the ORR was 86.7% (13/15), and the DCR was 100%. The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.

BEIJING and MADRID, Oct. 22, 2023 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce that the clinical data of glecirasib in combination with JAB-3312 was published in the form of a proffered paper presentation at the 2023 European Society for Medical Oncology Congress (ESMO 2023).

Jacobio presented results of a Phase I/IIa study of glecirasib in combination with JAB-3312. The trial consisted of seven dose groups, including glecirasib of 400 mg and 800 mg in combination with JAB-3312 at different doses and dosing intervals, aiming to explore the safety, efficacy, and tolerability through different dose groups, and to provide a basis for a subsequent registrational clinical trial. As of August 4, 2023, a total of 144 KRAS G12C mutant patients were enrolled, including 129 NSCLC patients, 14 patients with colorectal cancer, and 1 patient with pancreatic cancer.

Among the 129 NSCLC (non-small cell lung cancer) patients involved in the trial, 107 patients had undergone at least one tumor assessment using RECIST1.1 criteria, and 58 of them were first-line therapy patients (spread across the seven dose groups), with an ORR of 65.5% (38/58) and a DCR of 100%. The ORR was 86.7% (13/15) in the dose group[1] of 800 mg glecirasib in combination with 2 mg JAB-3312. The mPFS (median progression-free survival) and duration of response are still under observation as the patients are still undergoing treatment.

The incidence of grades 3 and 4 TRAEs (treatment-related adverse events) was 39.6% across all the dose groups, whereas the incidence of grades 3 and 4 TRAEs was 36.7% in the dose group [1] of 800 mg glecirasib in combination with 2 mg JAB-3312.

Relevant studies have shown that the SHP2 inhibitor is one of the most promising drug partners for the KRAS G12C inhibitor in NSCLC.

"In KRAS G12C mutant NSCLC patients, the combination therapy of glecirasib with JAB-3312 has shown positive efficacy signals. Compared with monotherapy, combination therapy can synergistically inhibit tumor growth. In addition, both drugs are administered orally, so patients do not need to be hospitalized, which is more convenient for patients," said Prof. Jie WANG from the Cancer Hospital, Chinese Academy of Medical Sciences, the principal investigator of this trial. "We look forward to further validating the clinical efficacy of the combination therapy through follow-up studies."

"The data provides the basis for the registrational clinical study of glecirasib in combination with SHP2 inhibitor. The research team will determine the following registrational clinical trial plan based on the optimal dose combination of this trial after the PFS data matures," said Andrea WANG-GILLAM M.D., Ph.D., Chief Medical Officer of Jacobio. "SHP2 is a target for which there are no approved or marketed inhibitors anywhere in the world. We hope that through this study, we can bring confidence to SHP2 inhibitor investigators, improve the response rate of the KRAS G12C inhibitor as monotherapy, prolong patients’ survival periods, and improve their quality of life."

[1] Once daily for 1 week on, then 1 week off.

For more information, please visit the official website of ESMO: https://www.esmo.org/.

Conference Call Information
Jacobio will host a live conference call on Oct. 24, 2023, at 14:00-15:00 (UTC+8). Participants must register in advance of the conference call. Registration Link: https://goldmansachs.zoom.us/webinar/register/WN_6sS33tpzRMWy2vFSPSx11Q

About Glecirasib
Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of Phase I/II clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China; a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, and combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer.

About JAB-3312
JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with glecirasib and other agents in China, the United States and Europe. 

About Jacobio
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people’s health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.

Source : Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network